The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InBiogen Inc. reported robust first-quarter results with revenue reaching $2.48 billion, driven by a surge in Leqembi sales, despite lowering its 2026 profit forecast due to acquisition charges. In parallel, PPG reported Q1 results where earnings per share matched analyst estimates, while revenues exceeded expectations bolstered by favorable currency gains. Unlike Biogen, PPG reaffirmed its full-year 2026 earnings guidance, maintaining its outlook despite the headwind of rising operational costs. Investors continue to monitor Biogen's upcoming Phase 2 CELIA data for BIIB080 as a critical mid-year milestone. Overall, market sentiment remains balanced as analysts weigh strong operational performance against long-term growth trajectories and cost pressures across these sectors.